Johnson & Johnson (JNJ)

Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.

Johnson & Johnson beat earnings this morning. Then its stock price dropped.

Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.

Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.

Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in its Innovative Medicine business offset slower-than-expected performance in parts of MedTech. The company raised its full-year sales outlook and said it re

Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.

These companies have a long history of dividend growth.

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

A 50-year dividend grower and a monthly income REIT; how J&J and Realty Income build lasting wealth for patient investors.

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Don't underestimate this healthcare giant.